PDF
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
The Board of Directors and CEO of Diagonal Bio AB hereby publish the Annual Report for the fiscal year 2023.
The Annual Report is available as an attached file to this release and on Diagonal Bio's website (www.diagonalbio.com/investors/financial-reports).
- Diagonal Bio AB Annual Report 2023
- PR - Diagonal Bio AB Annual Report 2023 - 2024-05-15
For more information, please contact:
Karin Wehlin, VD
Phone: +46 (0)70305 24 88
E-mail: kw@diagonalbio.com
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
E-mail: ca@skmg.se
About Diagonal Bio
Diagonal Bio AB was founded in 2020 and is a Swedish biotechnology company with headquarters and offices in Lund. The Company develops the PANVIRAL® platform to detect and diagnose small sections of pathogen genomes, for example viruses, bacteria and fungi. The Company was founded with the goal of reducing human suffering by revolutionizing global diagnostics of pathogen-borne diseases with proprietary technology. Diagonal Bio's patented technology can also be used for the less regulated market segments via LAMPlify®.